Zinzino acquires Valentus Global assets to boost European distribution and direct sales momentum

How is Zinzino expanding its reach through the Valentus Global acquisition?

Zinzino AB (publ.), a Sweden-based direct selling company specialising in personalised nutrition and wellness solutions, has acquired key assets from U.S.-registered Valentus Global Inc., including its distributor database, customer records, inventory, and intellectual property. The transaction, structured as an asset purchase, underscores Zinzino’s strategic focus on accelerating market penetration in Europe and bolstering its presence across North America. The acquisition is valued at SEK 20 million, with approximately half allocated to inventory.

Valentus Global, though headquartered in Delaware, has established a strong operational foothold in Europe, making it a compelling target for Zinzino’s aggressive expansion strategy. The company’s product lines align with Zinzino’s philosophy of biotechnology-based, test-driven wellness and personalised health. The newly acquired network adds immediate distribution power and market familiarity, particularly in regions where Zinzino has seen recent growth surges.

As with previous acquisitions—including VMA Life in 2020, Enhanzz in 2022, Xelliss and ACN in 2024, and Zurvita earlier in 2025—Zinzino continues to reinforce its vertically integrated business model. Its focus remains on direct selling and digital infrastructure to drive global wellness transformation through personalised nutrition plans based on cellular-level testing.

Why does the Valentus Global acquisition align with Zinzino’s growth model?

Zinzino’s acquisition strategy consistently targets synergistic organisations in the direct selling space, especially those with strong European networks and wellness-focused portfolios. Valentus Global fits this mould, offering not only a database of experienced distributors but also intellectual property that enhances Zinzino’s research-backed product portfolio. The acquisition facilitates rapid onboarding of new markets by leveraging existing customer relationships and inventory flow, without the logistical delays typical of greenfield expansion.

Dag Bergheim Pettersen, CEO of Zinzino, alongside Paul Person, CEO and owner of Valentus Global, described the transaction as a meeting of experience and a shared vision for personalised health solutions. Both leaders pointed to the growing relevance of tailored shopping and wellness journeys, which have accelerated in the post-pandemic digital economy. Zinzino intends to fully integrate Valentus Global’s network into its proprietary tech-first platform, enhancing distributor experiences through data-backed performance tools and streamlined logistics.

How is Zinzino performing financially following recent acquisitions?

The Valentus Global deal follows a robust first quarter for Zinzino, which reported a 60% year-over-year increase in group revenue for Q1 2025, reaching SEK 725.9 million. March alone delivered a 79% revenue surge to SEK 268 million, up from SEK 149.7 million a year earlier.

Geographically, the revenue uplift was broad-based. Central Europe saw quarterly growth of 66%, while Southern and Western Europe surged 79%, reinforcing the rationale for acquiring a Europe-focused entity like Valentus Global. North American sales spiked 217% year-over-year, and Asia-Pacific revenues jumped 427%, highlighting the company’s strengthening global footprint.

Faun Pharma, Zinzino’s contract manufacturing arm, recorded a 42% year-on-year decline in external sales to SEK 16.1 million. However, this appears to reflect Zinzino’s increasing vertical integration strategy, redirecting capacity toward internal product lines and strategic brand launches.

How has Zinzino’s stock responded to this growth momentum?

Zinzino’s strong operating results and strategic M&A activity have translated into exceptional equity market performance. As of April 11, 2025, Zinzino AB’s Class B shares (STO: ZZ.B) closed at SEK 144.80, marking a 0.84% daily gain. Over the past 12 months, the stock has appreciated by nearly 90%, significantly outperforming both the OMX Stockholm Benchmark Index and peers in the health and wellness direct selling sector.

In U.S. markets, Zinzino’s over-the-counter (OTC) shares (ZNZNF) mirrored this bullish trend, closing at $14.85 with a 2.41% daily gain and a staggering 290.79% increase over the past year. Market capitalization currently stands at approximately SEK 5.04 billion (about $513 million), underpinned by robust fundamentals and consistent earnings delivery.

The stock’s trailing twelve-month price-to-earnings (P/E) ratio is 31.55, with a forward P/E of 21.58, suggesting continued investor expectations for earnings acceleration. Zinzino also offers a dividend yield of 2.76%, with the next ex-dividend date scheduled for May 30, 2025.

Market sentiment surrounding Zinzino is strongly positive, supported by rising revenues, increased market share, and a well-executed acquisition roadmap. However, the elevated valuation compared to historical averages implies that much of the anticipated future growth is already priced in. Investors are advised to monitor Q2 and Q3 2025 results for clearer indicators on the integration success of Valentus Global and recent prior acquisitions.

From an investment perspective, Zinzino appears to be a strong “hold” for existing shareholders, with upside potential in the medium term. New investors may consider entry on price pullbacks or post-earnings confirmation, particularly as the company integrates its recent acquisitions and continues to expand in emerging markets.

What are the expected synergies from the Valentus Global acquisition?

The SEK 20 million asset purchase is expected to deliver strong operational and revenue synergies. Valentus Global generated more than SEK 50 million in revenue during 2024, mainly in regions where Zinzino has now established a significant presence. This overlap is expected to enable cross-selling, cost efficiencies, and higher conversion rates through Zinzino’s data-driven platform.

The onboarding of new distributors, already familiar with Valentus’s health offerings, should accelerate performance across Zinzino’s wellness ecosystem. Meanwhile, the acquired IP and inventory reduce initial R&D and manufacturing expenditure, while extending the shelf life of Zinzino’s existing product range.

How does this acquisition align with Zinzino’s long-term vision?

Zinzino’s long-term mission centres on reshaping the global wellness landscape through test-based nutrition, biotech-driven supplements, and direct-to-consumer education. By acquiring brands with overlapping values and distribution infrastructure, Zinzino is constructing a decentralised global network of wellness ambassadors equipped with advanced diagnostics and supply-chain support.

The integration of Valentus Global fits into this larger picture—providing immediate distributor depth, enhanced customer access, and intellectual property that strengthens Zinzino’s scientific and commercial value propositions. Looking ahead, the company’s performance will increasingly depend on its ability to maintain profitability while sustaining its expansion in North America, Asia-Pacific, and underpenetrated EU markets.